Thrombotic microangiopathy induced by oral contraceptive pills - a case report.
Abstract
phenotype. Here the characterized lesion is the arteriolar and capillary wall thickening, intra vascular
platelet fibrin thrombi and partial or complete vessel lumen occlusion. It is caused by complement
abnormalities, ADAMTS 13 deficiency, infections, pregnancy, drugs or metastatic carcinomas. Drugs
like quinine are proved causative factors for thrombotic microangiopathies1 and included as etiologic
factors in classification of TMAs. There are anecdotal reports of oral contraceptive pills causing
thrombotic microangiopathies. Here we describe a 37 year old female presenting with thrombotic
microangiopathy caused by oral contraceptive pills. She was successfully treated with plasmaphresis.
Full Text:
PDFReferences
N Besbas. A classification of hemolytic uremic syndrome and thrombotic Thrombocytopenic
purpura and related disorders. Kidney International
(2006) 70, 423–431.
Markus Hollenbeck. Haemolytic-uraemic syndrome and thrombotic- thrombocytopenic purpura in
adults: clinical findings and prognostic factors for death and end-stage renal disease. Nephrol
Dial Transplant (1998) 13: 76- 81.
Thomas Barbour. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial
Transplant (2012) 27: 2673–2685.
HAN-MOU TSAI. Advances in the Pathogenesis, Diagnosis, and Treatment of Thrombotic
Thrombocytopenic Purpura. J Am Soc Nephrol 14: 1072– 1081, 2003.
Marie Scully. Guidelines on the diagnosis and management of thrombotic thrombocytopenic
purpura and other thrombotic microangiopathies. British Journal of Haematology
doi:10.1111/j.1365-2141.2012.09167.
David Kavanagh. Atypical Hemolytic Uremic Syndrome. Seminars in Nephrology,
Vol33,No6,November2013,pp508–530.
Holdrinet RS, de Pauw BE, Haanen C: Hormonal dependent thrombotic thrombocytopenic
purpura (TTP). Scand J Haematol 1983, 30:250-256.
Vesconi S, Langer M, Rossi E, Mondonico P, Cambiaghi G, Donati MB: Thrombotic
thrombocytopenic purpura during oral contraceptive
treatment. Thromb Haemost 1979, 40:563-564.
Hauglustaine D, Van Damme B, Vanrenterghem Y, Michielsen P:Recurrent hemolytic uremic
syndrome during oral contraception.
Clin Nephrol 1981, 15:148-153.
Fraser JL, Millenson M, Malynn ER, Uhl L, Kruskall MS: Possible association between the
Norplant contraceptive system and thrombotic
thrombocytopenic purpura. Obstet Gynecol 1996,87:860-863.
Raife TJ, Lentz SR, Atkinson BS, Vesely SK, Hessner MJ: Factor V Leiden: a genetic risk factor
for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving
protease activity. Blood 2002, 99:437-442.
George JN, Vesely SK, Terrell DR. The Oklahoma thrombotic thrombocytopenic purpurahemolytic
uremic syndrome (TTP-HUS)
registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin
Hematol 2004; 41: 60–67.
Kostas Stylianou. Refractory thrombotic thrombocytopenic purpura associated with oral
contraceptives and factor V Leiden: a case report.
Cases Journal 2009, 2:6611.
JING SHAO. Protective Role of Nitric Oxide in a Model of Thrombotic Microangiopathy in Rats.
J Am Soc Nephrol 12: 2088–2097, 2001.
Ryan J. Goldberg. The Role of Endothelial Cell Injury in Thrombotic Microangiopathy. American
Journal of Kidney Diseases, Vol 56, No 6 (December), 2010: pp 1168-1174.
Piero Ruggenenti. The pathophysiology and management of thrombotic thrombocytopenic
purpura. Eur J Haematoll996: 56: 191-207.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An initiative of The Tamil Nadu Dr M.G.R. Medical University